Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Steinacker, Petra ^a   Fang, Lubin ^a   Kuhle, Jens ^b   Petzold, Axel ^c   Tumani, Hayrettin ^a   Ludolph, Albert C ^a   Otto, Markus ^a   Brettschneider, Johannes ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; NEUROFILAMENT H PROTEIN; NEUROFILAMENT PROTEIN; PROGRANULIN; SOLUBLE BETA AMYLOID PRECURSOR PROTEIN ALPHA; SOLUBLE BETA AMYLOID PRECURSOR PROTEIN BETA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GRN PROTEIN, HUMAN; ISOPROTEIN; NEUROFILAMENT PROTEIN H; SIGNAL PEPTIDE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; CEREBROSPINAL FLUID; FOLLOW UP; MIDDLE AGED; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; AGED, 80 AND OVER; AMYLOID BETA-PROTEIN PRECURSOR; AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEUROFILAMENT PROTEINS; PARKINSON DISEASE; PROGNOSIS; PROTEIN ISOFORMS; ROC CURVE; YOUNG ADULT;

EID: 80051696970     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023600     Document Type: Article

References (32)

1. Strong M, Rosenfeld J, (2003) Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord 4: 136-143.
2. Beghi E, Logroscino G, Chio A, Hardiman O, Mitchell D, et al. (2006) The epidemiology of ALS and the role of population-based registries. Biochim Biophys Acta 1762: 1150-1157.
3. Fischer LR, Glass JD, (2007) Axonal degeneration in motor neuron disease. Neurodegener Dis 4: 431-442.
4. Winhammar JM, Rowe DB, Henderson RD, Kiernan MC, (2005) Assessment of disease progression in motor neuron disease. Lancet Neurol 4: 229-238.
5. Turner MR, Kiernan MC, Leigh PN, Talbot K, (2009) Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 8: 94-109.
6. Sussmuth SD, Sperfeld AD, Hinz A, Brettschneider J, Endruhn S, et al. (2010) CSF glial markers correlate with survival in amyotrophic lateral sclerosis. Neurology 74: 982-987.
7. Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tumani H, (2006) Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 66: 852-856.
8. Tumani H, Teunissen C, Sussmuth S, Otto M, Ludolph AC, et al. (2008) Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Expert Rev Mol Diagn 8: 479-494.
9. Steinacker P, Hendrich C, Sperfeld AD, Jesse S, Lehnert S, et al. (2009) Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. J Neural Transm 116: 1169-1178.
10. Copanaki E, Chang S, Vlachos A, Tschape JA, Muller UC, et al. (2010) sAPPalpha antagonizes dendritic degeneration and neuron death triggered by proteasomal stress. Mol Cell Neurosci 44: 386-393.
11. (1996) The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch Neurol 53: 141-147.
12. Kleyweg RP, van der Meche FG, Schmitz PI, (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle Nerve 14: 1103-1109.
13. Petzold A, (2005) Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 233: 183-198.
14. Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM, (2007) Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neurol 14: 1329-1333.
15. Zhang YJ, Xu YF, Dickey CA, Buratti E, Baralle F, et al. (2007) Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci 27: 10530-10534.
16. Brooks BR, Miller RG, Swash M, Munsat TL, (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1: 293-299.
17. Silberstein SD, Olesen J, Bousser MG, Diener HC, Dodick D, et al. (2005) The International Classification of Headache Disorders, 2nd Edition (ICHD-II)-revision of criteria for 8.2 Medication-overuse headache. Cephalalgia 25: 460-465.
18. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ, (1992) What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 42: 1142-1146.
19. Hoehn MM, Yahr MD, (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427-442.
20. Ehehalt R, Michel B, De Pietri Tonelli D, Zacchetti D, Simons K, et al. (2002) Splice variants of the beta-site APP-cleaving enzyme BACE1 in human brain and pancreas. Biochem Biophys Res Commun 293: 30-37.
21. Tampellini D, Magrane J, Takahashi RH, Li F, Lin MT, et al. (2007) Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J Biol Chem 282: 18895-18906.
22. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, et al. (2010) Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry 15: 138-145.
23. Kuhle J, Regeniter A, Leppert D, Mehling M, Kappos L, et al. (2010) A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J Neuroimmunol 220: 114-119.
24. Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ, (2003) A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 278: 179-190.
25. Youden WJ, (1950) Index for rating diagnostic tests. Cancer 3: 32-35.
26. Turner PR, O'Connor K, Tate WP, Abraham WC, (2003) Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70: 1-32.
27. Chyung AS, Greenberg BD, Cook DG, Doms RW, Lee VM, (1997) Novel beta-secretase cleavage of beta-amyloid precursor protein in the endoplasmic reticulum/intermediate compartment of NT2N cells. J Cell Biol 138: 671-680.
28. Sennvik K, Fastbom J, Blomberg M, Wahlund LO, Winblad B, et al. (2000) Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 278: 169-172.
29. Bodansky A, Kim JM, Tempest L, Velagapudi A, Libby R, et al. (2010) TDP-43 and ubiquitinated cytoplasmic aggregates in sporadic ALS are low frequency and widely distributed in the lower motor neuron columns independent of disease spread. Amyotroph Lateral Scler 11: 321-327.
30. Mattson MP, (2000) Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 1: 120-129.
31. Kogel D, Schomburg R, Schurmann T, Reimertz C, Konig HG, et al. (2003) The amyloid precursor protein protects PC12 cells against endoplasmic reticulum stress-induced apoptosis. J Neurochem 87: 248-256.
32. Ilieva EV, Ayala V, Jove M, Dalfo E, Cacabelos D, et al. (2007) Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain 130: 3111-3123.